Business
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $460 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar sold 7,637,931 shares of common stock in the offering, which includes 1,034,482 shares sold upon exercise in full by the underwriters of their option to p
About this update from Nektar Therapeutics
[{"type":"text","content":"SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $460 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar sold 7,637,931 shares of common stock in the offering, which includes 1,034,482 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering, and 293,103 pre-funded warrants. The shares of common stock were sold at a public offering price of $58.00 per share and the pre-funded warrants to purchase shares of common stock were sold at a public offering price of $57.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price of each pre-funded warrant. The gross proceeds to Nektar from the offering were approximately $460 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the securities sold in this offering were offered by Nektar.","length":1246,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Nektar Therapeutics)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Nektar Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":145,"url":"https://media.zenfs.com/en/prnewswire.com/e9141883926ab6553b7ec849fd9c6537"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ls4zow06UG_HUOQnS5yvKw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e9141883926ab6553b7ec849fd9c6537","width":400,"height":145}},"href":"https://mma.prnewswire.com/media/1390052/Nektar_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Jefferies, TD Cowen, and Piper Sandler acted as joint bookrunning managers for the offering. Oppenheimer & Co. and H.C. Wainwright & Co. acted as lead managers and B. Riley Securities acted as manager for the offering.","length":226,"tagName":"p"},{"type":"text","content":"The securities described above were offered pursuant to a shelf registration statement on Form S-3ASR (No. 333-291466) that was filed with th...